Intravenous Immunoglobulin Market: Global Industry Analysis and forecast (2022-2029)

Intravenous Immunoglobulin Market is expected to grow at a CAGR of 5% during the forecast period. global Intravenous Immunoglobulin Market is expected to reach US$ 19.44 Bn. by 2029. Intravenous Immunoglobulin MarketTo know about the Research Methodology :- Request Free Sample Report Intravenous Immunoglobulin Market Drivers and Restrains: Immunoglobulins are the glycoprotein molecules produced by the plasma or the white blood cells in response to antigens, which are foreign to the immune system. They are obtained from blood by fractionation process and purified for therapeutic and nontherapeutic applications. This, coupled with the proven efficiency of the immunoglobulins as an effective treatment option for a number of immune diseases and the lack of training. Different classes of immunoglobulin such as IgG, IgA, and IgM are used for the treatment of several immunological and neurological diseases.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. The intravenous immunoglobulin market has driven by factors like rising incidence of immunodeficiency diseases, increasing adoption of immunoglobulin replacement therapy and rising geriatric population. However, stringent regulations pertaining to production and approval and cost Intensive nature of immunoglobulin replacement therapy are major restraining factored the market growth at global level.

Intravenous Immunoglobulin Market Segmentation Analysis:

Based on the indication, the intravenous immunoglobulin market has been segmented into chronic inflammatory demyelinating polyneuropathy (CIDP), Primary humoral immunodeficiency, Idiopathic thrombocytopenic purpura (ITP), Guillain-Barre syndrome, Myasthenia gravis, Multifocal motor neuropathy (MMN), Kawasaki disease, Hypogammaglobulinemia, Chronic lymphocytic leukemia. The hypogammaglobulinemia segment was the highest contributor to the market in 2021, and is expected to maintain its dominance throughout the forecast period. This is attributed to the significant rise in the incidence of hypogammaglobulinemia disorder around the world over the years. For instance, hypogammaglobulinemia is the most common chronic immune defect in patients with lymphoproliferative disorders (LPDs). Its incidence rate is nearly xx% per xx population yearly, globally.

Intravenous Immunoglobulin Market Regional Insights:

Geographically, the Intravenous Immunoglobulin market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America held the largest share xx% of the Intravenous Immunoglobulin market in 2021 owing to superior health care infrastructure, strong regional economics, easy access to advanced technology, and rise in reimbursement initiatives. According to the Immune Deficiency Foundation (IDF), almost xx people per xx in the U.S. suffer from primary immunodeficiency and there are over xx million undiagnosed cases in the country. The intravenous immunoglobulin market in Asia Pacific is witnessing strong growth, attributed to increase in inpatient population and rise in usage of IVIG by end-users such as hospitals and clinics. Emerging countries in Asia Pacific such as China and India are poised to be the most promising markets for IVIG in the near future. Large underserved patient population, extensive development of health care infrastructure, and rise in emphasis on research and development in the health care sector are major driving factors of the market growth. Intravenous Immunoglobulin Market Competitive landscape Major Key players operating in this market are Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG. Manufacturers in the intravenous immunoglobulin are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers. The objective of the report is to present comprehensive analysis of intravenous immunoglobulin market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding intravenous immunoglobulin market dynamics, structure by analyzing the market segments, and project the intravenous immunoglobulin market size. Clear representation of competitive analysis of key players by product type, price, financial position, product portfolio, growth strategies, and regional presence in the intravenous immunoglobulin market make the report investor’s guide.

Intravenous Immunoglobulin Market Scope: Inquire before buying

Intravenous Immunoglobulin Market, by Indication:

• Chronic inflammatory demyelinating Polyneuropathy (CIDP) • Primary humoral immunodeficiency • Idiopathic thrombocytopenic purpura (ITP) • Guillain-Barre syndrome • Myasthenia gravis • Multifocal motor neuropathy (MMN) • Kawasaki disease • Hypogammaglobulinemia • Chronic lymphocytic leukemia

Intravenous Immunoglobulin Market, by End User:

• Hospitals • Clinics • Home Care

Intravenous Immunoglobulin Market, by Region:

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Intravenous Immunoglobulin Market, Key Players:

• Baxter international Inc. • CSL Ltd. • Grifols S.A • Octapharma AG • Kedrion Biopharma Inc. • LFB group • Biotest AG • China Biologics Products, Inc. • Takeda Pharmaceuticals • Bayer Healthcare • Hualan Biological Engineering Inc. • Omrix Biopharmaceuticals Ltd. • Behring GmbH • Shanghai RAAS Blood Products Co., Ltd. • Option Care Enterprises, Inc. • ADMA Biologics, Inc. • BioScrip, Inc. • Bio Products Laboratory Limited • ABEONA THERAPEUTICS • BDI Pharma • Biotest AG Frequently Asked Questions: 1. Which region has the largest share in Global Intravenous Immunoglobulin Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Global Intravenous Immunoglobulin Market? Ans: The Global Intravenous Immunoglobulin Market is growing at a CAGR of 5% during forecasting period 2022-2029. 3. What is scope of the Global Intravenous Immunoglobulin market report? Ans: Global Intravenous Immunoglobulin Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Intravenous Immunoglobulin market? Ans: The important key players in the Global Intravenous Immunoglobulin Market are – Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, China Biologics Products, Inc., Takeda Pharmaceuticals, Bayer Healthcare, Hualan Biological Engineering Inc., Omrix Biopharmaceuticals Ltd., Behring GmbH, Shanghai RAAS Blood Products Co., Ltd., Option Care Enterprises, Inc., ADMA Biologics, Inc., BioScrip, Inc., Bio Products Laboratory Limited, ABEONA THERAPEUTICS, BDI Pharma, and Biotest AG 5. What is the study period of this market? Ans: The Global Intravenous Immunoglobulin Market is studied from 2021 to 2029.
Intravenous Immunoglobulin Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Intravenous Immunoglobulin Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 4.8. Patent Registration 5. Supply Side and Demand Side Indicators 6. Global Intravenous Immunoglobulin Market Analysis and Forecast 6.1. Global Intravenous Immunoglobulin Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Intravenous Immunoglobulin Market Analysis and Forecast, by Indication 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Intravenous Immunoglobulin Market Value Share Analysis, by Indication 7.4. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by Indication 7.5. Global Intravenous Immunoglobulin Market Analysis, by Indication 7.6. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by Indication 8. Global Intravenous Immunoglobulin Market Analysis and Forecast, by End User 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Intravenous Immunoglobulin Market Value Share Analysis, by End User 8.4. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by End User 8.5. Global Intravenous Immunoglobulin Market Analysis, by End User 8.6. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by End User 9. Global Intravenous Immunoglobulin Market Analysis, by Region 9.1. Global Intravenous Immunoglobulin Market Value Share Analysis, by Region 9.2. Global Intravenous Immunoglobulin Market Size (US$ Bn) Forecast, by Region 9.3. Global Intravenous Immunoglobulin Market Attractiveness Analysis, by Region 10. North America Intravenous Immunoglobulin Market Analysis 10.1. Key Findings 10.2. North America Intravenous Immunoglobulin Market Overview 10.3. North America Intravenous Immunoglobulin Market Value Share Analysis, by Indication 10.4. North America Intravenous Immunoglobulin Market Forecast, by Indication 10.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 10.4.2. Primary humoral immunodeficiency 10.4.3. Idiopathic thrombocytopenic purpura (ITP) 10.4.4. Guillain-Barre syndrome 10.4.5. Myasthenia gravis 10.4.6. Multifocal motor neuropathy (MMN) 10.4.7. Kawasaki disease 10.4.8. Hypogammaglobulinemia 10.4.9. Chronic lymphocytic leukemia 10.5. North America Intravenous Immunoglobulin Market Value Share Analysis, by End User 10.6. North America Intravenous Immunoglobulin Market Forecast, by End User 10.6.1. Hospitals 10.6.2. Clinics 10.6.3. Home Care 10.7. North America Intravenous Immunoglobulin Market Value Share Analysis, by Country 10.8. North America Intravenous Immunoglobulin Market Forecast, by Country 10.8.1. U.S. 10.8.2. Canada 10.9. North America Intravenous Immunoglobulin Market Analysis, by Country 10.10. U.S. Intravenous Immunoglobulin Market Forecast, by Indication 10.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 10.10.2. Primary humoral immunodeficiency 10.10.3. Idiopathic thrombocytopenic purpura (ITP) 10.10.4. Guillain-Barre syndrome 10.10.5. Myasthenia gravis 10.10.6. Multifocal motor neuropathy (MMN) 10.10.7. Kawasaki disease 10.10.8. Hypogammaglobulinemia 10.10.9. Chronic lymphocytic leukemia 10.11. U.S. Intravenous Immunoglobulin Market Forecast, by End User 10.11.1. Hospitals 10.11.2. Clinics 10.11.3. Home Care 10.12. Canada Intravenous Immunoglobulin Market Forecast, by Indication 10.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 10.12.2. Primary humoral immunodeficiency 10.12.3. Idiopathic thrombocytopenic purpura (ITP) 10.12.4. Guillain-Barre syndrome 10.12.5. Myasthenia gravis 10.12.6. Multifocal motor neuropathy (MMN) 10.12.7. Kawasaki disease 10.12.8. Hypogammaglobulinemia 10.12.9. Chronic lymphocytic leukemia 10.13. Canada Intravenous Immunoglobulin Market Forecast, by End User 10.13.1. Hospitals 10.13.2. Clinics 10.13.3. Home Care 10.14. North America Intravenous Immunoglobulin Market Attractiveness Analysis 10.14.1. By Indication 10.14.2. By End User 10.15. PEST Analysis 10.16. Key Trends 10.17. Key Development 11. Europe Intravenous Immunoglobulin Market Analysis 11.1. Key Findings 11.2. Europe Intravenous Immunoglobulin Market Overview 11.3. Europe Intravenous Immunoglobulin Market Value Share Analysis, by Indication 11.4. Europe Intravenous Immunoglobulin Market Forecast, by Indication 11.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.4.2. Primary humoral immunodeficiency 11.4.3. Idiopathic thrombocytopenic purpura (ITP) 11.4.4. Guillain-Barre syndrome 11.4.5. Myasthenia gravis 11.4.6. Multifocal motor neuropathy (MMN) 11.4.7. Kawasaki disease 11.4.8. Hypogammaglobulinemia 11.4.9. Chronic lymphocytic leukemia 11.5. Europe Intravenous Immunoglobulin Market Value Share Analysis, by End User 11.6. Europe Intravenous Immunoglobulin Market Forecast, by End User 11.6.1. Hospitals 11.6.2. Clinics 11.6.3. Home Care 11.7. Europe Intravenous Immunoglobulin Market Value Share Analysis, by Country 11.8. Europe Intravenous Immunoglobulin Market Forecast, by Country 11.8.1. Germany 11.8.2. U.K. 11.8.3. France 11.8.4. Italy 11.8.5. Spain 11.8.6. Rest of Europe 11.9. Europe Intravenous Immunoglobulin Market Analysis, by Country 11.10. Germany Intravenous Immunoglobulin Market Forecast, by Indication 11.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.10.2. Primary humoral immunodeficiency 11.10.3. Idiopathic thrombocytopenic purpura (ITP) 11.10.4. Guillain-Barre syndrome 11.10.5. Myasthenia gravis 11.10.6. Multifocal motor neuropathy (MMN) 11.10.7. Kawasaki disease 11.10.8. Hypogammaglobulinemia 11.10.9. Chronic lymphocytic leukemia 11.11. Germany Intravenous Immunoglobulin Market Forecast, by End User 11.11.1. Hospitals 11.11.2. Clinics 11.11.3. Home Care 11.12. U.K. Intravenous Immunoglobulin Market Forecast, by Indication 11.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.12.2. Primary humoral immunodeficiency 11.12.3. Idiopathic thrombocytopenic purpura (ITP) 11.12.4. Guillain-Barre syndrome 11.12.5. Myasthenia gravis 11.12.6. Multifocal motor neuropathy (MMN) 11.12.7. Kawasaki disease 11.12.8. Hypogammaglobulinemia 11.12.9. Chronic lymphocytic leukemia 11.13. U.K. Intravenous Immunoglobulin Market Forecast, by End User 11.13.1. Hospitals 11.13.2. Clinics 11.13.3. Home Care 11.14. France Intravenous Immunoglobulin Market Forecast, by Indication 11.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.14.2. Primary humoral immunodeficiency 11.14.3. Idiopathic thrombocytopenic purpura (ITP) 11.14.4. Guillain-Barre syndrome 11.14.5. Myasthenia gravis 11.14.6. Multifocal motor neuropathy (MMN) 11.14.7. Kawasaki disease 11.14.8. Hypogammaglobulinemia 11.14.9. Chronic lymphocytic leukemia 11.15. France Intravenous Immunoglobulin Market Forecast, by End User 11.15.1. Hospitals 11.15.2. Clinics 11.15.3. Home Care 11.16. Italy Intravenous Immunoglobulin Market Forecast, by Indication 11.16.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.16.2. Primary humoral immunodeficiency 11.16.3. Idiopathic thrombocytopenic purpura (ITP) 11.16.4. Guillain-Barre syndrome 11.16.5. Myasthenia gravis 11.16.6. Multifocal motor neuropathy (MMN) 11.16.7. Kawasaki disease 11.16.8. Hypogammaglobulinemia 11.16.9. Chronic lymphocytic leukemia 11.17. Italy Intravenous Immunoglobulin Market Forecast, by End User 11.17.1. Hospitals 11.17.2. Clinics 11.17.3. Home Care 11.18. Spain Intravenous Immunoglobulin Market Forecast, by Indication 11.18.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.18.2. Primary humoral immunodeficiency 11.18.3. Idiopathic thrombocytopenic purpura (ITP) 11.18.4. Guillain-Barre syndrome 11.18.5. Myasthenia gravis 11.18.6. Multifocal motor neuropathy (MMN) 11.18.7. Kawasaki disease 11.18.8. Hypogammaglobulinemia 11.18.9. Chronic lymphocytic leukemia 11.19. Spain Intravenous Immunoglobulin Market Forecast, by End User 11.19.1. Hospitals 11.19.2. Clinics 11.19.3. Home Care 11.20. Rest of Europe Intravenous Immunoglobulin Market Forecast, by Indication 11.20.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 11.20.2. Primary humoral immunodeficiency 11.20.3. Idiopathic thrombocytopenic purpura (ITP) 11.20.4. Guillain-Barre syndrome 11.20.5. Myasthenia gravis 11.20.6. Multifocal motor neuropathy (MMN) 11.20.7. Kawasaki disease 11.20.8. Hypogammaglobulinemia 11.20.9. Chronic lymphocytic leukemia 11.21. Rest of Europe Intravenous Immunoglobulin Market Forecast, by End User 11.21.1. Hospitals 11.21.2. Clinics 11.21.3. Home Care 11.22. Europe Intravenous Immunoglobulin Market Attractiveness Analysis 11.22.1. By Indication 11.22.2. By End User 11.23. PEST Analysis 11.24. Key Trend 11.25. Key Development 12. Asia Pacific Intravenous Immunoglobulin Market Analysis 12.1. Key Findings 12.2. Asia Pacific Intravenous Immunoglobulin Market Overview 12.3. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by Indication 12.4. Asia Pacific Intravenous Immunoglobulin Market Forecast, by Indication 12.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.4.2. Primary humoral immunodeficiency 12.4.3. Idiopathic thrombocytopenic purpura (ITP) 12.4.4. Guillain-Barre syndrome 12.4.5. Myasthenia gravis 12.4.6. Multifocal motor neuropathy (MMN) 12.4.7. Kawasaki disease 12.4.8. Hypogammaglobulinemia 12.4.9. Chronic lymphocytic leukemia 12.5. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by End User 12.6. Asia Pacific Intravenous Immunoglobulin Market Forecast, by End User 12.6.1. Hospitals 12.6.2. Clinics 12.6.3. Home Care 12.7. Asia Pacific Intravenous Immunoglobulin Market Value Share Analysis, by Country 12.8. Asia Pacific Intravenous Immunoglobulin Market Forecast, by Country 12.8.1. China 12.8.2. India 12.8.3. Japan 12.8.4. ASEAN 12.8.5. Rest of Asia Pacific 12.9. Asia Pacific Intravenous Immunoglobulin Market Analysis, by Country 12.10. China Intravenous Immunoglobulin Market Forecast, by Indication 12.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.10.2. Primary humoral immunodeficiency 12.10.3. Idiopathic thrombocytopenic purpura (ITP) 12.10.4. Guillain-Barre syndrome 12.10.5. Myasthenia gravis 12.10.6. Multifocal motor neuropathy (MMN) 12.10.7. Kawasaki disease 12.10.8. Hypogammaglobulinemia 12.10.9. Chronic lymphocytic leukemia 12.11. China Intravenous Immunoglobulin Market Forecast, by End User 12.11.1. Hospitals 12.11.2. Clinics 12.11.3. Home Care 12.12. India Intravenous Immunoglobulin Market Forecast, by Indication 12.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.12.2. Primary humoral immunodeficiency 12.12.3. Idiopathic thrombocytopenic purpura (ITP) 12.12.4. Guillain-Barre syndrome 12.12.5. Myasthenia gravis 12.12.6. Multifocal motor neuropathy (MMN) 12.12.7. Kawasaki disease 12.12.8. Hypogammaglobulinemia 12.12.9. Chronic lymphocytic leukemia 12.13. India Intravenous Immunoglobulin Market Forecast, by End User 12.13.1. Hospitals 12.13.2. Clinics 12.13.3. Home Care 12.14. Japan Intravenous Immunoglobulin Market Forecast, by Indication 12.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.14.2. Primary humoral immunodeficiency 12.14.3. Idiopathic thrombocytopenic purpura (ITP) 12.14.4. Guillain-Barre syndrome 12.14.5. Myasthenia gravis 12.14.6. Multifocal motor neuropathy (MMN) 12.14.7. Kawasaki disease 12.14.8. Hypogammaglobulinemia 12.14.9. Chronic lymphocytic leukemia 12.15. Japan Intravenous Immunoglobulin Market Forecast, by End User 12.15.1. Hospitals 12.15.2. Clinics 12.15.3. Home Care 12.16. ASEAN Intravenous Immunoglobulin Market Forecast, by Indication 12.16.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.16.2. Primary humoral immunodeficiency 12.16.3. Idiopathic thrombocytopenic purpura (ITP) 12.16.4. Guillain-Barre syndrome 12.16.5. Myasthenia gravis 12.16.6. Multifocal motor neuropathy (MMN) 12.16.7. Kawasaki disease 12.16.8. Hypogammaglobulinemia 12.16.9. Chronic lymphocytic leukemia 12.17. ASEAN Intravenous Immunoglobulin Market Forecast, by End User 12.17.1. Hospitals 12.17.2. Clinics 12.17.3. Home Care 12.18. Rest of Asia Pacific Intravenous Immunoglobulin Market Forecast, by Indication 12.18.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 12.18.2. Primary humoral immunodeficiency 12.18.3. Idiopathic thrombocytopenic purpura (ITP) 12.18.4. Guillain-Barre syndrome 12.18.5. Myasthenia gravis 12.18.6. Multifocal motor neuropathy (MMN) 12.18.7. Kawasaki disease 12.18.8. Hypogammaglobulinemia 12.18.9. Chronic lymphocytic leukemia 12.19. Rest of Asia Pacific Intravenous Immunoglobulin Market Forecast, by End User 12.19.1. Hospitals 12.19.2. Clinics 12.19.3. Home Care 12.20. Asia Pacific Intravenous Immunoglobulin Market Attractiveness Analysis 12.20.1. By Indication 12.20.2. By End User 12.21. PEST Analysis 12.22. Key Trend 12.23. Key Development 13. Middle East & Africa Intravenous Immunoglobulin Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Intravenous Immunoglobulin Market Overview 13.3. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by Indication 13.4. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Indication 13.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 13.4.2. Primary humoral immunodeficiency 13.4.3. Idiopathic thrombocytopenic purpura (ITP) 13.4.4. Guillain-Barre syndrome 13.4.5. Myasthenia gravis 13.4.6. Multifocal motor neuropathy (MMN) 13.4.7. Kawasaki disease 13.4.8. Hypogammaglobulinemia 13.4.9. Chronic lymphocytic leukemia 13.5. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by End User 13.6. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by End User 13.6.1. Hospitals 13.6.2. Clinics 13.6.3. Home Care 13.7. Middle East & Africa Intravenous Immunoglobulin Market Value Share Analysis, by Country 13.8. Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Country 13.8.1. GCC 13.8.2. South Africa 13.8.3. Rest of Middle East & Africa 13.9. Middle East & Africa Intravenous Immunoglobulin Market Analysis, by Country 13.10. GCC Intravenous Immunoglobulin Market Forecast, by Indication 13.10.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 13.10.2. Primary humoral immunodeficiency 13.10.3. Idiopathic thrombocytopenic purpura (ITP) 13.10.4. Guillain-Barre syndrome 13.10.5. Myasthenia gravis 13.10.6. Multifocal motor neuropathy (MMN) 13.10.7. Kawasaki disease 13.10.8. Hypogammaglobulinemia 13.10.9. Chronic lymphocytic leukemia 13.11. GCC Intravenous Immunoglobulin Market Forecast, by End User 13.11.1. Hospitals 13.11.2. Clinics 13.11.3. Home Care 13.12. South Africa Intravenous Immunoglobulin Market Forecast, by Indication 13.12.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 13.12.2. Primary humoral immunodeficiency 13.12.3. Idiopathic thrombocytopenic purpura (ITP) 13.12.4. Guillain-Barre syndrome 13.12.5. Myasthenia gravis 13.12.6. Multifocal motor neuropathy (MMN) 13.12.7. Kawasaki disease 13.12.8. Hypogammaglobulinemia 13.12.9. Chronic lymphocytic leukemia 13.13. South Africa Intravenous Immunoglobulin Market Forecast, by End User 13.13.1. Hospitals 13.13.2. Clinics 13.13.3. Home Care 13.14. Rest of Middle East & Africa Intravenous Immunoglobulin Market Forecast, by Indication 13.14.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 13.14.2. Primary humoral immunodeficiency 13.14.3. Idiopathic thrombocytopenic purpura (ITP) 13.14.4. Guillain-Barre syndrome 13.14.5. Myasthenia gravis 13.14.6. Multifocal motor neuropathy (MMN) 13.14.7. Kawasaki disease 13.14.8. Hypogammaglobulinemia 13.14.9. Chronic lymphocytic leukemia 13.15. Rest of Middle East & Africa Intravenous Immunoglobulin Market Forecast, by End User 13.15.1. Hospitals 13.15.2. Clinics 13.15.3. Home Care 13.16. Middle East & Africa Intravenous Immunoglobulin Market Attractiveness Analysis 13.16.1. By Indication 13.16.2. By End User 13.17. PEST Analysis 13.18. Key Trend 13.19. Key Development 14. South America Intravenous Immunoglobulin Market Analysis 14.1. Key Findings 14.2. South America Intravenous Immunoglobulin Market Overview 14.3. South America Intravenous Immunoglobulin Market Value Share Analysis, by Indication 14.4. South America Intravenous Immunoglobulin Market Forecast, by Indication 14.4.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 14.4.2. Primary humoral immunodeficiency 14.4.3. Idiopathic thrombocytopenic purpura (ITP) 14.4.4. Guillain-Barre syndrome 14.4.5. Myasthenia gravis 14.4.6. Multifocal motor neuropathy (MMN) 14.4.7. Kawasaki disease 14.4.8. Hypogammaglobulinemia 14.4.9. Chronic lymphocytic leukemia 14.5. Others South America Intravenous Immunoglobulin Market Value Share Analysis, by End User 14.6. South America Intravenous Immunoglobulin Market Forecast, by End User 14.6.1. Hospitals 14.6.2. Clinics 14.6.3. Home Care 14.7. South America Intravenous Immunoglobulin Market Value Share Analysis, by Country 14.8. South America Intravenous Immunoglobulin Market Forecast, by Country 14.8.1. Brazil 14.8.2. Mexico 14.8.3. Rest of South America 14.9. Brazil Intravenous Immunoglobulin Market Forecast, by Indication 14.9.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 14.9.2. Primary humoral immunodeficiency 14.9.3. Idiopathic thrombocytopenic purpura (ITP) 14.9.4. Guillain-Barre syndrome 14.9.5. Myasthenia gravis 14.9.6. Multifocal motor neuropathy (MMN) 14.9.7. Kawasaki disease 14.9.8. Hypogammaglobulinemia 14.9.9. Chronic lymphocytic leukemia 14.10. Brazil Intravenous Immunoglobulin Market Forecast, by End User 14.10.1. Hospitals 14.10.2. Clinics 14.10.3. Home Care 14.11. Mexico Intravenous Immunoglobulin Market Forecast, by Indication 14.11.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 14.11.2. Primary humoral immunodeficiency 14.11.3. Idiopathic thrombocytopenic purpura (ITP) 14.11.4. Guillain-Barre syndrome 14.11.5. Myasthenia gravis 14.11.6. Multifocal motor neuropathy (MMN) 14.11.7. Kawasaki disease 14.11.8. Hypogammaglobulinemia 14.11.9. Chronic lymphocytic leukemia 14.12. Mexico Intravenous Immunoglobulin Market Forecast, by End User 14.12.1. Hospitals 14.12.2. Clinics 14.12.3. Home Care 14.13. Rest of South America Intravenous Immunoglobulin Market Forecast, by Indication 14.13.1. Chronic inflammatory demyelinating Polyneuropathy (CIDP) 14.13.2. Primary humoral immunodeficiency 14.13.3. Idiopathic thrombocytopenic purpura (ITP) 14.13.4. Guillain-Barre syndrome 14.13.5. Myasthenia gravis 14.13.6. Multifocal motor neuropathy (MMN) 14.13.7. Kawasaki disease 14.13.8. Hypogammaglobulinemia 14.13.9. Chronic lymphocytic leukemia 14.14. Rest of South America Intravenous Immunoglobulin Market Forecast, by End User 14.14.1. Hospitals 14.14.2. Clinics 14.14.3. Home Care 14.15. South America Intravenous Immunoglobulin Market Attractiveness Analysis 14.15.1. By Indication 14.15.2. By End User 14.16. PEST Analysis 14.17. Key Trend 14.18. Key Development 15. Company Profiles 15.1. Market Share Analysis, by Company 15.2. Competition Matrix 15.2.1. Competitive Benchmarking of key players by price, presence, market share, End Users and R&D investment 15.2.2. New Product Launches and Product Enhancements 15.2.3. Market Consolidation 15.2.3.1. M&A by Regions, Investment and End Users 15.2.3.2. M&A Key Players, Forward Integration and Backward Integration 15.3. Company Profiles: Key Players 15.3.1. Baxter international Inc. 15.3.1.1. Company Overview 15.3.1.2. Financial Overview 15.3.1.3. Product Portfolio 15.3.1.4. Business Strategy 15.3.1.5. Recent Developments 15.3.1.6. Company Footprint 15.3.2. CSL Ltd. 15.3.3. Grifols S.A 15.3.4. Octapharma AG 15.3.5. Kedrion Biopharma Inc. 15.3.6. LFB group 15.3.7. Biotest AG 15.3.8. China Biologics Products, Inc. 15.3.9. Takeda Pharmaceuticals 15.3.10. Bayer Healthcare 15.3.11. Hualan Biological Engineering Inc. 15.3.12. Omrix Biopharmaceuticals Ltd. 15.3.13. Behring GmbH 15.3.14. Shanghai RAAS Blood Products Co., Ltd. 15.3.15. Option Care Enterprises, Inc. 15.3.16. ADMA Biologics, Inc. 15.3.17. BioScrip, Inc. 15.3.18. Bio Products Laboratory Limited 15.3.19. ABEONA THERAPEUTICS 15.3.20. BDI Pharma 15.3.21. Biotest AG 16. Primary Key Insights

About This Report

Report ID 38783
Category Healthcare
Published Date Nov 2019
Updated Date Aug 2022
Contact Us